145 related articles for article (PubMed ID: 29434001)
1. Validation and implementation of Planova™ BioEX virus filters in the manufacture of a new liquid intravenous immunoglobulin in China.
Ma S; Pang GL; Shao YJ; Hongo-Hirasaki T; Shang MX; Inouye M; Jian CY; Zhu MZ; Yang HH; Gao JF; Xi ZY; Song DW
Biologicals; 2018 Mar; 52():37-43. PubMed ID: 29434001
[TBL] [Abstract][Full Text] [Related]
2. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
3. Characterizing the impact of pressure on virus filtration processes and establishing design spaces to ensure effective parvovirus removal.
Strauss D; Goldstein J; Hongo-Hirasaki T; Yokoyama Y; Hirotomi N; Miyabayashi T; Vacante D
Biotechnol Prog; 2017 Sep; 33(5):1294-1302. PubMed ID: 28556575
[TBL] [Abstract][Full Text] [Related]
4. Integrity testing of Planova™ BioEX virus removal filters used in the manufacture of biological products.
Sekine S; Komuro M; Sohka T; Sato T
Biologicals; 2015 May; 43(3):186-94. PubMed ID: 25753822
[TBL] [Abstract][Full Text] [Related]
5. Effect of pH, NaCl concentration, and mAb concentration of feed solution on the filterability of Planova™ 20N and Planova™ BioEX.
Hashikawa-Muto C; Yokoyama Y; Hamamoto R; Kobayashi K; Masuda Y; Nonaka K
Biotechnol Prog; 2024; 40(2):e3420. PubMed ID: 38146091
[TBL] [Abstract][Full Text] [Related]
6. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance.
Parkkinen J; Rahola A; von Bonsdorff L; Tölö H; Törmä E
Vox Sang; 2006 Feb; 90(2):97-104. PubMed ID: 16430667
[TBL] [Abstract][Full Text] [Related]
7. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
Caballero S; Nieto S; Gajardo R; Jorquera JI
Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
[TBL] [Abstract][Full Text] [Related]
8. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
9. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
[TBL] [Abstract][Full Text] [Related]
10. Choice of parvovirus model for validation studies influences the interpretation of the effectiveness of a virus filtration step.
Nowak T; Popp B; Roth NJ
Biologicals; 2019 Jul; 60():85-92. PubMed ID: 31105022
[TBL] [Abstract][Full Text] [Related]
11. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
12. Virus filter scalability: Demonstration of consistent viral clearance across laboratory and manufacturing scales.
Buesing B; Schwartz A; Shah A; Sohka T; Hirotomi N; Strauss D
Biologicals; 2021 Jul; 72():27-32. PubMed ID: 34226123
[TBL] [Abstract][Full Text] [Related]
13. Integration of Planova filters in manufacturing processes of biologicals improve the virus safety effectively: A review of publicly available data.
Gröner A
Biotechnol Prog; 2024; 40(1):e3398. PubMed ID: 37985214
[TBL] [Abstract][Full Text] [Related]
14. Effects of varying virus-spiking conditions on a virus-removal filter Planova™ 20N in a virus validation study of antibody solutions.
Hongo-Hirasaki T; Yamaguchi K; Yanagida K; Hayashida H; Ide S
Biotechnol Prog; 2011; 27(1):162-9. PubMed ID: 21312364
[TBL] [Abstract][Full Text] [Related]
15. Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: Impact of membrane structure and localization of captured virus particles.
Adan-Kubo J; Tsujikawa M; Takahashi K; Hongo-Hirasaki T; Sakai K
Biotechnol Prog; 2019 Nov; 35(6):e2875. PubMed ID: 31228338
[TBL] [Abstract][Full Text] [Related]
16. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
[TBL] [Abstract][Full Text] [Related]
17. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
18. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
19. Analysis of filtration behavior using integrated column chromatography followed by virus filtration.
Shirataki H; Yokoyama Y; Taniguchi H; Azeyanagi M
Biotechnol Bioeng; 2021 Sep; 118(9):3569-3580. PubMed ID: 34032276
[TBL] [Abstract][Full Text] [Related]
20. Meeting report--workshop on virus removal by filtration: trends and new developments.
Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Kreil TR; Robertson JS; Ruffing M; Ruiz S
PDA J Pharm Sci Technol; 2013; 67(2):98-104. PubMed ID: 23569071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]